CELL INTELLIGENCE · 肿瘤细胞治疗研究

通过靶向肿瘤相关巨噬细胞的嵌合受体工程化溶瘤病毒重振内源性抗肿瘤免疫

Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages.

结合胶原蛋白的 IL-15 免疫细胞因子武装溶瘤腺病毒建立自我强化的免疫刺激环境以增强抗肿瘤免疫

Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immun

免疫细胞因子特征可预测接受溶瘤腺病毒 TILT-123 联合化疗及无 IL-2 过继性 TIL 治疗的晚期黑色素瘤患者的生存

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-fr

这些发现为 TILT-123 联合 TIL 疗法提供了机制上的见解，并为未来的生物标志物导向临床研究提出了方向。

CAR-T 细胞治疗胰腺癌的进展、挑战与创新策略

Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.

利用多特异性抗体实现新一代肿瘤治疗

Harnessing multispecific antibodies for next-generation cancer treatments.

病毒感染与癌症：从机制到治疗

Virus infections and cancers: from mechanisms to therapeutics.

从单克隆到多功能免疫治疗：用溶瘤病毒重编程 B 细胞恶性肿瘤中的 CAR-T 细胞疗法

From monoclonal to polyfunctional immunotherapy: Reprogramming CAR-T-cell therapy with oncolytic viruses in B-cell malignancies.

利用多模式肿瘤免疫疗法增强溶瘤病毒的疗效

Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses.

放疗增强新型溶瘤疱疹病毒 VG161 的溶瘤效果并放大其在乳腺癌中的抗肿瘤免疫

Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer.

来那度胺通过 CD28、Notch 信号通路及 IL-2 释放增强 CD1d-Vδ2 双特异性抗体介导的 Vγ9Vδ2-T 细胞效应功能

Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.

我们的发现为在 CD1d 表达的血液系统恶性肿瘤患者中探索 CD1d-Vδ2 bsTCE 与 IMiD 来那度胺的联合治疗提供了依据。